Multiple keratoacanthomas arising in the setting of sorafenib therapy: Novel chemoprophylaxis with bexarotene

Cancer Control

Volumn 16, Issue 1, 2009, Pages 66-69

  Marquez, Christina B ^a,c   Smithberger, Erica E ^a   Bair, Sarah M ^a,b   Wenham, Robert M ^b   Fenske, Neil A ^a,b   Glass, L Frank ^b   Cherpelis, Basil S ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c FLORIDA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; CA 125 ANTIGEN; CARBOPLATIN; DOCETAXEL; FENOFIBRATE; LEVOTHYROXINE; PACLITAXEL; SORAFENIB; TAMOXIFEN; THYROXINE; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE; TETRALIN DERIVATIVE;

ADULT; ARTICLE; CASE REPORT; CHEMOPROPHYLAXIS; CYTOREDUCTIVE SURGERY; DRUG DOSE INCREASE; FEMALE; HUMAN; KERATOACANTHOMA; LEG; METASTASIS; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; NOSE; OVARY CANCER; PAPULE; ADENOCARCINOMA; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CYSTADENOCARCINOMA; DOSE RESPONSE; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; SKIN DISEASE; TUMOR RECURRENCE;

ADENOCARCINOMA, PAPILLARY; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARBOPLATIN; CLINICAL TRIALS AS TOPIC; CYSTADENOCARCINOMA, SEROUS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; KERATOACANTHOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PACLITAXEL; PYRIDINES; SKIN DISEASES; TETRAHYDRONAPHTHALENES;

EID: 61449320511     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327480901600110     Document Type: Article

References (10)

1. Kong HH, Cowen EW, Azad NS, et al. Keratoacanthomas associated with sorafenib therapy. J Am Acad Dermatol. 2006;56(1):171-172.
2. Roberts LR. Sorafenib in liver cancer: just the beginning. N Engl J Med. 2008;359(4):420-422.
3. Autier J, Escudier B, Wechsler J, et al. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol. 2008;144(7):886-S92.
4. Dubauskas Z, Kunishige J, Prieto VG, et al. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib: a single institution experience. J Clin Oncol. 2008 ASCO Annu Meet Proc (Post-Meet Ed). 2008;26(15 Suppl). Abstract 16101.
5. Kossard S, Tan K, Choy C. Keratoacanthoma and infundibulocystic squamous cell carcinoma. Am J Dermatopathol. 2008;30(2):127-134.
6. Feldman RJ, Maize JC. Multiple keratoacanthomas in a young woman: report of a case emphasizing medical management and a review of the spectrum of multiple keratoacanthomas. Int J Dermatol. 2007;46(1):77-79.
7. Rosenblum GA. Multiple palmar keratoacanthomas treated with acitretin. J Drugs Dermatol. 2006;5(10):1006-1009.
8. Assaf C, BagotM, Drummer R, et al. Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. Br J Dermatol. 2006;155(2):261-266.
9. Talpur R, Ward S, Apisarnthanarax N, et al. Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 2002;47(5): 672-684.
10. Gniadecki R, Assaf C, Bagot M, et al. The optimal use of bexarotene in cutaneous T-cell lymphoma. Br J Dermatol. 2007;157(3):433-440. Epub 2007 Jun 6.